Laser Industries (Israel) progresses in non-laser business:
This article was originally published in Clinica
Laser Industries (Israel) has received US FDA approval for its Sharplan U Sight system, an ultrasound device to assist surgeons and gynaecologists to detect liver/colon tumours or ductal stones during laparoscopy. The clearance marks the completion of one phase of the company's strategy, established three years ago, of developing several non-laser products for the minimally invasive surgical market. Other than the U Sight, products in this line include the I Sight computerised endoscopic video camera and the Bi Sight, which offers the surgeon a combined video and ultrasound image of the endoscopic surgical site on a single screen.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.